Regenerative Medicine's Second Act: From Cell Therapy to Actual Organs

A Turning Point That Is Also a Reality Check

Regenerative medicine has spent close to three decades as one of biotech’s most reliably oversold categories — the promise of growing replacement tissue, reversing degenerative disease at its source, and eventually manufacturing whole organs on demand has produced more magazine covers than approved products. That is starting to change, unevenly and slower than the more enthusiastic coverage suggests, but genuinely: the field is now commonly sized at roughly $28 billion in 2026, anchored by a handful of real approvals rather than pure pipeline promise, and artificial intelligence is beginning to show up as a measurable accelerant rather than a marketing addition — a Nature Biotechnology study found machine learning models trained on multi-omics data could predict optimal induced pluripotent stem cell differentiation conditions with 94 percent accuracy, cutting protocol development time by 38 percent, part of a broader pattern estimated to be compressing R&D timelines across the field by 30 to 40 percent.

The honest framing for where the category actually stands requires holding two facts at once, and most coverage of regenerative medicine only ever mentions one. Mesenchymal stem cell therapy has produced a genuine, if singular, FDA approval and a large, rapidly growing trial base. Induced pluripotent stem cell therapy — the more scientifically ambitious platform, capable in principle of becoming almost any cell type in the body — has produced an enormous amount of exciting early data and not a single completed, approved product. Understanding why those two closely related technologies are at such different stages is most of what a venture investor needs to know before writing a check in this space.

Mesenchymal Stem Cells: The Quiet Front-Runner

Mesenchymal stem cells — multipotent adult cells, typically sourced from bone marrow, umbilical cord tissue, or adipose tissue, capable of differentiating into a meaningful but limited range of tissue types — reached a genuine milestone in December 2024, when Ryoncil became the first FDA-approved mesenchymal stem cell therapy in the United States, for pediatric steroid-refractory graft-versus-host disease. That single approval, arriving after a genuinely difficult multi-year regulatory path, has functioned as a proof of concept for the entire modality, and the trial activity behind it is now substantial: more than 1,760 active clinical trials on ClinicalTrials.gov are testing MSC-based therapy across more than 920 distinct medical conditions, with roughly 89 new trials launched in 2025 alone, a 37 percent year-on-year increase.

South Korea, not the United States, is the actual global leader in approved MSC products, with nine separate approvals domestically — out of twelve approved MSC therapies worldwide — reflecting a more permissive and, depending on one’s view, more risk-tolerant regulatory approach to conditional approval for cell-based products than the FDA has historically taken. That gap between where the regulatory frontier actually sits and where most Western investors assume it sits is worth noting on its own: a venture investor building a global regenerative-medicine thesis who is only tracking FDA approvals is missing most of the actual commercial precedent.

The reason MSCs have moved faster than more scientifically ambitious platforms is mechanistic, not just regulatory. MSCs carry no meaningful tumor risk and none of the ethical controversy that once shadowed embryonic stem cell research, and — critically for manufacturing economics, a theme covered in more depth elsewhere in this issue’s treatment of cell and gene therapy — they can be sourced allogeneically and banked off-the-shelf, avoiding the patient-specific, batch-of-one manufacturing bottleneck that constrains autologous cell therapies like most currently approved CAR-T products.

iPSCs: Still Waiting for a First Approval

Induced pluripotent stem cells are adult cells — typically taken from skin or blood — reprogrammed in the lab to behave like embryonic stem cells, capable in principle of differentiating into any of the roughly two hundred cell types found in the human body. That versatility is exactly why the platform generates so much scientific excitement, and exactly why it has proven so much harder to actually get through clinical development and approval than mesenchymal stem cell therapy. As of 2026, no iPSC-derived therapy has completed a full three-phase clinical trial program and received FDA approval, even as a genuinely large number of iPSC-derived candidates are advancing through earlier-stage trials globally, spanning neurology, ophthalmology, oncology, and autoimmune disease.

The pipeline is real, even if the finish line has not yet been reached by anyone. Gameto’s Fertilo, an iPSC-based fertility therapy, received FDA clearance for its trial program and is now in Phase 3. Fate Therapeutics’ FT819, an off-the-shelf iPSC-derived CAR T-cell candidate, holds FDA Regenerative Medicine Advanced Therapy designation and is heading toward a registrational trial for systemic lupus erythematosus, alongside earlier-stage iPSC-derived natural killer cell programs from the same company. China-based iRegene Therapeutics’ NouvNeu001, targeting Parkinson’s disease, became the first allogeneic iPSC-derived cell therapy globally to hold both FDA Fast Track and RMAT designations simultaneously, built on a chemically induced reprogramming approach distinct from the genetic reprogramming methods used elsewhere in the field.

A recurring technical thread across nearly all of these programs is the effort to solve immune rejection at the platform level rather than the patient level — engineering "hypoimmune" or universal donor iPSC lines, selected or edited for specific HLA haplotypes that minimize the chance a recipient’s immune system will reject cells that did not originate from their own body. Solving that problem well is close to the central unlock for iPSC therapy ever reaching the same off-the-shelf, allogeneic manufacturing economics that have made MSC therapy commercially tractable years ahead of it.

The RMAT Pathway, and Why It Matters

The FDA’s Regenerative Medicine Advanced Therapy designation, referenced throughout the programs above, functions similarly to Breakthrough Therapy designation in other therapeutic areas — available to products showing early clinical evidence of addressing a serious condition, and carrying with it more frequent and substantive engagement with the FDA during development, along with eligibility for accelerated approval pathways where appropriate. It has become the primary regulatory signal investors in this category track as a leading indicator of a program’s credibility, given how early-stage and scientifically uncertain most regenerative medicine programs still are relative to more established therapeutic modalities — an RMAT designation does not guarantee eventual approval, but it is a genuine, FDA-conferred marker that a program’s early data has cleared a real bar.

Tissue Engineering’s Honest Progress Report

The tissue engineering and organ bioprinting side of regenerative medicine tells a genuinely different story from the cell therapy side, and it is worth being precise about where the real progress has and has not occurred, since public coverage of this specific sub-field tends toward the most dramatic possible framing. Relatively simple, structurally uncomplicated tissues — cultured skin grafts, tissue-engineered bladders, and increasingly tracheal reconstructions, including patient-customized bioprinted tracheal implants now in clinical trial protocols in South Korea — are already in clinical use or advanced trials, and represent genuine, if incremental, clinical wins.

Complex solid organs — kidney, liver, heart, lung — remain a considerably more distant proposition, and the reason is consistent across nearly every serious technical review of the field: vascularization. A simple tissue construct like a skin graft or a bladder can survive on diffusion and simple perfusion while it integrates with a host. A kidney or a liver needs an intricate, functioning network of blood vessels, capable of carrying oxygen and nutrients to every cell in a dense three-dimensional structure, present and functional essentially from the moment of implantation. Building that vascular network artificially, at the resolution and complexity a real organ requires, remains the central unsolved engineering problem in the field — not the underlying cell biology, which has advanced considerably, but the physical plumbing.

Two broad technical approaches are competing to solve pieces of that problem. Decellularization takes a cadaveric or animal organ, strips it of its original cells using detergents and enzymes, and leaves behind the organ’s natural structural scaffold — including, crucially, its existing vascular architecture — which is then repopulated with a patient’s own or donor-matched cells. Three-dimensional bioprinting builds a structure from scratch, depositing living cells suspended in a biomaterial "bioink" layer by layer according to a digital blueprint, offering more design flexibility but starting from nothing rather than borrowing nature’s already-solved vascular architecture. Harvard’s Wyss Institute and several other academic groups have made genuine recent progress on 3D-printed vascularized tissue constructs specifically targeting this bottleneck, including recent published work on engineering functional kidney collecting-duct systems — a meaningfully smaller and more tractable problem than a whole functioning kidney, but a real, publishable step toward one.

Where This Overlaps — and Doesn’t — With Cell and Gene Therapy

It is worth being explicit about how this category relates to the cell and gene therapy manufacturing thesis discussed elsewhere in this issue, since the two are adjacent enough to blur together in casual conversation but are genuinely distinct investment theses. That earlier piece focused specifically on the manufacturing economics of genetically engineered cell therapies — CAR-T and gene-edited products, most of them still autologous, batch-of-one processes with the cost and scalability problems that implies. Regenerative medicine, as covered here, is broader and in several important respects easier: MSC therapy in particular does not require genetic modification at all, is inherently allogeneic and bankable at scale, and has already cleared a real FDA approval — a materially more advanced commercial and manufacturing position than most gene-edited cell therapies currently occupy. Tissue engineering and organ bioprinting are a third, still-distinct category again, with a manufacturing model — physical fabrication of a structural scaffold rather than biological expansion of a cell population — that shares little with either cell therapy approach.

Where the Venture Opportunity Actually Sits

For a concentrated healthcare portfolio, the near-term, evidenced opportunity sits with MSC-platform companies building toward specific, well-defined indications with a credible regulatory path — the Ryoncil precedent, narrow as it is, is a genuine existence proof that this modality can clear FDA review, and the more than 1,760 active trials represent a large, still largely unconsolidated field of candidates. The iPSC platform opportunity is earlier-stage and higher-risk by construction, given that no program globally has yet closed the loop from trial to approval, but the hypoimmune, universal-donor engineering work specifically is the technical unlock worth tracking closely, since it is the piece of science that would let iPSC therapy inherit MSC therapy’s allogeneic manufacturing economics rather than repeating autologous cell therapy’s cost structure.

Tissue engineering and organ bioprinting remain, honestly, a longer-horizon bet than most venture fund lifecycles comfortably accommodate for the complex-organ endpoint specifically — a functioning bioprinted kidney is not a five-year story. The nearer-term, genuinely investable slice of that category is the simpler structural tissue work already reaching clinical use, and the underlying vascularization science itself, which has applications well beyond whole-organ fabrication, including improving graft survival in more conventional reconstructive and orthopedic procedures.

For our own operating geographies specifically, MSC therapy’s allogeneic, bankable manufacturing model deserves particular attention — it is structurally the regenerative-medicine modality best suited to the kind of regional manufacturing hub model discussed elsewhere in this issue’s treatment of cell and gene therapy access in India and East Africa, since it avoids the per-patient, apheresis-dependent supply chain that makes autologous therapies so difficult to deliver outside a handful of the world’s most resourced health systems.

What "Second Act" Actually Means Here

Regenerative medicine’s first act was two decades of promise substantially outrunning delivery — real, worthwhile science that took far longer than early enthusiasm suggested to produce a single approved product. The second act, underway now, is defined less by any single breakthrough than by the field finally sorting itself into legible tiers of maturity: MSC therapy with real regulatory precedent and manufacturing economics that work today, iPSC therapy with genuine momentum but an approval still to come, and tissue engineering with real near-term wins on simple structures and a genuinely difficult, still-unsolved problem sitting between here and a transplantable organ. Underwriting the category well now means treating those three tiers as three separate theses with three separate risk profiles, not one undifferentiated "regenerative medicine" bet — which is, more often than not, how the category’s first two decades of overpromising actually happened in the first place.